Kancera Management

Management criteria checks 1/4

Kancera's CEO is Peter Selin, appointed in Jul 2023, has a tenure of less than a year. directly owns 0.022% of the company’s shares, worth €3.98K. The average tenure of the management team and the board of directors is 0.8 years and 12.3 years respectively.

Key information

Peter Selin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.02%
Management average tenure	less than a year
Board average tenure	12.3yrs

Recent management updates

Recent updates

CEO

Peter Selin (50 yo)

less than a year

Tenure

Mr. Peter Selin serves as Chief Executive Officer of Kancera AB (publ) since July 1, 2023. He had been an Executive Vice president of Corporate Development & Finance at Kancera AB (publ) since May 01, 2022...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Olin	Executive VP	less than a year	kr3.57m	0.27% SEK 49.0k
Peter Selin	Chief Executive Officer	less than a year	no data	0.022% SEK 4.0k
Hans Richter	Chief Financial Officer	no data	no data	no data
Niclas Brynne	Head of Clinical Development	no data	no data	0.024% SEK 4.2k
Markus Jerling	Chief Medical Officer	less than a year	no data	no data

0.8yrs

Average Tenure

65yo

Average Age

Experienced Management: 3EE0's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Olin	Executive VP	14.3yrs	kr3.57m	0.27% SEK 49.0k
Charlotte Edenius	Independent Director	7.9yrs	kr125.00k	0.0060% SEK 1.1k
Håkan Mellstedt	Independent Director	14.3yrs	kr125.00k	0.17% SEK 30.9k
Erik Nerpin	Independent Chairman of the Board	14.3yrs	kr175.00k	0.24% SEK 42.6k
Carl-Henrik Heldin	Independent Director	12.3yrs	kr125.00k	0.12% SEK 21.4k
Anders Gabrielsen	Independent Director	5.8yrs	kr125.00k	no data
Petter Brodin	Independent Director	3yrs	kr75.00k	no data

12.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 3EE0's board of directors are seasoned and experienced ( 12.3 years average tenure).

Kancera Management

Management criteria checks 1/4

Key information

Recent management updates

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Insufficient new directors

Insufficient new directors

Recent updates

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

New major risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: €0.21

New 90-day low: €0.22

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: €0.37

First half earnings released

New 90-day high - €0.30

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age